Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Cardiovascular Surgery Detailing Preclinical and Clinical Evaluation of SETALIUMTM Vascular Sealant

Posted by fidest press agency su sabato, 18 Maggio 2019

TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today the publication of its manuscript detailing preclinical and clinical evaluations of SETALIUMTM Vascular Sealant, the company’s first synthetic, biodegradable, on-demand, light-activated sealant.The results of these evaluations, published in The Journal of Cardiovascular Surgery on May 10th, 2019, ultimately showed that SETALIUM™ Vascular Sealant has good biocompatibility, good bioresorption, and a beneficial safety and efficacy profile.SETALIUMTM Vascular Sealant is a new synthetic on-demand, light-activated poly (glycerol sebacate) acrylate (PGSA), and pre-clinical and clinical studies were designed to assess the biocompatibility of this product, as well as its performance in living subjects. Pre-clinical trials included three successful large animal studies during which open vascular carotid and aortic reconstruction surgeries were performed. With these promising results, clinical trials were initiated in patients requiring carotid endarterectomy using an ePTFE patch.Biocompatibility testing demonstrated that standard clinical doses of the SETALIUMTM Vascular Sealant, and 40 times that dose, did not induce any significant toxic reaction. Animal studies produced excellent performance and safety data.Clinically significant hemostasis was achieved in 100% of the animals across carotid and aorta studies. In clinical studies, immediate hemostasis was achieved in 84% of cases with no device-related adverse events reported.As a result, the SETALIUM™ Vascular Sealant showed good biocompatibility, and an acceptable safety profile. In human trials, it was shown to be a safe and effective option that can achieve fast hemostasis in vascular carotid reconstructions.
TISSIUM is a privately-owned life sciences company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customization to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: